N8 Respiratory LLC, an emerging respiratory therapeutics company focused on treatment of chronic cystic fibrosis pulmonary infections,
announced new results from a preclinical study demonstrating its lead compound CSA-13’s efficacy as an antimicrobial peptide mimic against Pseudomonas aeruginosa. The study will be presented as a poster at the North American Cystic Fibrosis Conference (NACFC) in Atlanta, GA.
The study measured efficacy and the MIC of CSA-13 and tobramycin when combined with standard and tobramycin-resistant strains of P. aeruginosa. Sputum of cystic fibrosis patients was also added to each treatment to determine the impact of biofilm on each treatment. Results showed that the minimum inhibitory concentration (MIC) of CSA-13 was unchanged in the presence of sputum from CF patients, while the MIC of tobramycin (the most common antibiotic for pulmonary P. aeruginosa infections) increased significantly in the presence of sputum from CF patients. CSA-13’s MIC also remained unchanged whether tested in a tobramycin susceptible, or a tobramycin resistant strain.
“This is an encouraging study, as it demonstrates the ability of CSA-13 to remain effective even in the presence of sputum from a cystic fibrosis patient,” said Paul B. Savage, MD, Department of Chemistry and Biochemistry, Brigham Young University. “Further, it confirms previous findings that the compound may continue to be effective even in antibiotic-resistant strains of P. aeruginosa.”
- N8 Respiratory LLC announced results from a preclinical study demonstrating CSA-13’s effectiveness as an antimicrobial peptide mimic against Pseudomonas aeruginosa
- The study measured efficacy of CSA-13 and tobramycin when combined with standard and tobramycin-resistant strains of P. aeruginosa and analyzed the sputum of cystic fibrosis patients to determine the impact of biofilm on each treatment
- Successful findings were presented at the NACFC in Atlanta, Georgia this October